Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Annals of Oncology

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDG209PMID 12702527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current strategies of antibody-based treatment in Hodgkin's disease.

  2002cited by this paper
• A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

  2002cited by this paper
• The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.

  2001cited by this paper
• Recombinant anti‐CD25 immunotoxin RFT5(SCFV)‐ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice

  2000cited by this paper
• A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.

  2000cited by this paper
• Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.

  2000cited by this paper
• Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning

  2000cited by this paper
• Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

  2000cited by this paper
• Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

  2000cited by this paper
• Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

  1999cited by this paper
• Purification and characterization of lymphocyte chymase I, a granzyme implicated in perforin-mediated lysis.

  1998cited by this paper
• Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.

  1998cited by this paper
• BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

  1998cited by this paper
• A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.

  1997cited by this paper
• Targeted antibodies in the treatment of lymphomas.

  1997cited by this paper
• Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.

  1997cited by this paper
• Development of immunotoxins for potential clinical use in Hodgkin's disease.

  1996cited by this paper
• A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

  1996cited by this paper
• Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.

  1996cited by this paper
• Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.

  1996cited by this paper
• Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells.

  1996cited by this paper
• Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.

  1996cited by this paper
• Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.

  1995cited by this paper
• Development of new ricin A‐chain immunotoxins with potent anti‐tumor effects against human hodgkin cells in vitro and disseminated Hodgkin tumors in scid mice using high‐affinity monoclonal antibodies directed against the CD30 antigen

  1995cited by this paper
• Cocktails of ricin a‐chain immunotoxins against different antigens on hodgkin and sternberg‐reed cells have superior anti‐tumor effects against H‐RS cells in vitro and solid Hodgkin tumors in mice

  1995cited by this paper
• Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.

  1994cited by this paper
• Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma

  1994cited by this paper
• Phase I trial of an interleukin‐2 fusion toxin (DAB486IL‐2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy

  1994cited by this paper
• Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

  1994cited by this paper
• Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.

  1994cited by this paper
• Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.

  1993cited by this paper
• Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

  1993cited by this paper
• Immunotoxins: magic bullets or misguided missiles?

  1993cited by this paper
• Immunotoxins: magic bullets or misguided missiles?

  1993cited by this paper
• A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

  1993cited by this paper
• Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.

  1993cited by this paper
• The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.

  1992cited by this paper
• Indications for autologous bone marrow transplantation in Hodgkin's disease.

  1992cited by this paper
• Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.

  1992cited by this paper
• Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.

  1991cited by this paper
• Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.

  1991cited by this paper
• Phase I immunotoxin trial in patients with B-cell lymphoma.

  1991cited by this paper
• Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

  1990cited by this paper
• The immunophenotype of reed‐sternberg cells. A study of 50 cases of Hodgkin' disease using fixed frozen tissues

  1989cited by this paper
• Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

  1988cited by this paper
• Europium-labelled target cells in an assay of natural killer cell activity. II. A novel non-radioactive method based on time-resolved fluorescence. significance and specificity of the method.

  1986cited by this paper
• Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence.

  1986cited by this paper
• The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

  1985cited by this paper
• Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease.

  1984cited by this paper
• Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.

  1982cited by this paper
• Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis

  1980cited by this paper
• Combination chemotherapy in the treatment of advanced Hodgkin's disease.

  1975cited by this paper
• Combination chemotherapy in the treatment of advanced Hodgkin's disease.

  1970cited by this paper

• Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions

  2025cites this paper
• Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology

  2024cites this paper
• CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

  2023cites this paper
• Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes

  2023cites this paper
• Directing ricin-based immunotoxins with targeting affibodies and KDEL signal peptide to cancer cells effectively induces apoptosis and tumor suppression

  2022cites this paper
• Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges

  2021cites this paper
• Immunotoxins and nanobody-based immunotoxins: review and update

  2021cites this paper
• Atomic-resolution structures of type I ribosome inactivating protein alpha-momorcharin with different substrate analogs.

  2020cites this paper
• Hodgkin's lymphoma

  2020cites this paper
• Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties

  2020cites this paper
• Targeting Receptors on Cancer Cells with Protein Toxins

  2020cites this paper
• Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis

  2019cites this paper
• Ricin and Ricinus communis in pharmacology and toxicology-from ancient use and “Papyrus Ebers” to modern perspectives and “poisonous plant of the year 2018”

  2019cites this paper
• Dangerous plants in dermatology: Legal and controlled.

  2018cites this paper
• Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin.

  2018cites this paper
• Ricin Chapter 16 RICIN

  2018cites this paper
• Generation and characterization of angiogenin mutants as improved effector domains for H22(scFv)-based cytolytic fusion proteins

  2017cites this paper
• Toward Artificial Immunotoxins: Traceless Reversible Conjugation of RNase A with Receptor Targeting and Endosomal Escape Domains.

  2017cites this paper
• Clinical targeting recombinant immunotoxins for cancer therapy

  2017influential citation
• Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview

  2016cites this paper
• A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead

  2016cites this paper
• CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

  2016cites this paper
• Antibody-mediated delivery of therapeutics for cancer therapy

  2016cites this paper
• Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants

  2015cites this paper
• The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas

  2015cites this paper
• Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins

  2015cites this paper
• Biologic agents in the management of Hodgkin lymphoma.

  2015cites this paper
• Prognostic Biomarkers for Hodgkin Lymphoma

  2015cites this paper
• CD30 as a Therapeutic Target for Lymphoma

  2014cites this paper
• Ribosome‐inactivating Proteins in Cancer Treatment

  2014cites this paper
• Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy

  2014cites this paper
• Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

  2014cites this paper
• Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.

  2014cites this paper
• Bioreducible Polycations as Shuttles for Therapeutic Nucleic Acid and Protein Transfection

  2014cites this paper
• Medicinal plants for women's healthcare in southeast Asia: a meta-analysis of their traditional use, chemical constituents, and pharmacology.

  2014cites this paper
• Advances in anticancer antibody-drug conjugates and immunotoxins.

  2013cites this paper
• Current Status and Biomedical Applications of Ribosome-Inactivating Proteins

  2013cites this paper
• Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins

  2013cites this paper
• Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro

  2013cites this paper
• Antibody-based Therapeutics for the Treatment of Human B cell Malignancies

  2013cites this paper
• Targeted Toxins in Cancer Immunotherapy

  2013cites this paper
• Ribosome-inactivating proteins

  2013cites this paper
• A computational perspective of molecular interactions through virtual screening, pharmacokinetic and dynamic prediction on ribosome toxin A chain and inhibitors of Ricinus communis

  2012cites this paper
• Ricin Perspective in Bioterrorism

  2012cites this paper
• A Review on the Challenges for Increased Production of Castor

  2012cites this paper
• Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

  2012cites this paper
• Antibody-Based Immunotoxins for the Treatment of Cancer

  2012cites this paper
• Transient injury-dependent up-regulation of CD105 and its specific targeting with an anti-vascular anti-mouse endoglin-nigrin b immunotoxin.

  2012cites this paper
• A Ribosome-inactivating Protein Toxin as a Template for Cancer Drug Discovery

  2012cites this paper
• Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components

  2011cites this paper
• CD30: an important new target in hematologic malignancies

  2011cites this paper
• Targeted Drug Delivery Using Immunoconjugates: Principles and Applications

  2011cites this paper
• Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen

  2011cites this paper
• Passive and Active Vaccination Strategies to Prevent Ricin Poisoning

  2011cites this paper
• In vivo efficacy of the recombinant anti‐CD64 immunotoxin H22(scFv)‐ETA′ in a human acute myeloid leukemia xenograft tumor model

  2011cites this paper
• Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases

  2011cites this paper
• Therapeutic potential of anticancer immunotoxins.

  2011cites this paper
• A single point mutation in ricin A-chain increases toxin degradation and inhibits EDEM1-dependent ER retrotranslocation.

  2011cites this paper
• Toxin-Based Therapeutic Approaches

  2010cites this paper
• Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin

  2010cites this paper
• Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.

  2010cites this paper
• Ribosome-Inactivating Protein-Containing Conjugates for Therapeutic Use

  2010cites this paper
• Hodgkin's Lymphoma

  2010cites this paper
• Immune-based therapeutics for pediatric cancer

  2010cites this paper
• Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein.

  2009cites this paper
• An extract from Ricinus communis L. leaves possesses cytotoxic properties and induces apoptosis in SK-MEL-28 human melanoma cells

  2009cites this paper
• Drug development for recurrent and refractory classical Hodgkin lymphoma

  2009cites this paper
• Therapeutic targets of the TNF superfamily

  2009cites this paper
• Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.

  2009cites this paper
• Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo.

  2009cites this paper
• Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.

  2009cites this paper
• Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy

  2008cites this paper
• Tumor targeting using liposomal antineoplastic drugs

  2008cites this paper
• Regulatory T cells as therapeutic target in Hodgkin's lymphoma.

  2008cites this paper
• Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.

  2008cites this paper
• Yttrium-90 Ibritumomab Tiuxetan-Induced Complete Remission in a Patient with Classical Lymphocyte-Rich Hodgkin’s Lymphoma

  2008cites this paper
• Regulatory T cells as therapeutic target in Hodgkin's lymphoma

  2008cites this paper
• CELL-TARGETED RIBOSOME-INACTIVATING PROTEINS DERIVED FROM PROTEIN COMBINATORIAL LIBRARIES

  2008cites this paper
• Ricin and related toxins: review and perspective.

  2008cites this paper
• Anaplastic Large-Cell Lymphoma

  2007cites this paper
• Immunotoxin treatment of cancer.

  2007cites this paper
• Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.

  2007cites this paper
• Individualized target therapy of malignant lymphomas: an outlook.

  2007cites this paper
• Structure-function study of maize ribosome-inactivating protein: implications for the internal inactivation region and the sole glutamate in the active site

  2007cites this paper
• Immunotoxins for Glioma Therapy

  2007cites this paper
• Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin.

  2007cites this paper
• Co-application of ricin A chain and a recombinant adenovirus expressing ricin B chain as a novel approach for cancer therapy

  2007cites this paper
• Technology Insight: cytotoxic drug immunoconjugates for cancer therapy

  2007cites this paper
• Immunotoxins in the treatment of hematologic malignancies.

  2006cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies.

  2006cites this paper
• Management of early stage Hodgkin's lymphoma.

  2006cites this paper
• Radio-immunotherapy in low-grade non-Hodgkin's lymphoma.

  2005cites this paper
• [Plant lectins and their effects on cancer].

  2005cites this paper
• Immunotherapy of Hodgkin's lymphoma

  2005cites this paper
• Targeting of cytotoxic peptides to haematological malignancies

  2005cites this paper
• Lectinas vegetales y sus efectos en el cáncer

  2005cites this paper
• New anti-T cell immunotoxins for the clinic.

  2005cites this paper
• Arming antibodies for cancer therapy.

  2005cites this paper
• Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.

  2005cites this paper